Literature DB >> 6690395

Role of C3 in the control of monocyte C2 production.

A O Hamilton, L Morrison, W S Kilpatrick, D Lappin, J C Bensa, D W Riches, K Whaley.   

Abstract

Serum-treated antigen-antibody complexes (IC) and DTSP-polymerized C3b and C3c inhibited the production of the second complement component (C2) by monocytes in culture, whereas monomeric C3, C3b, C3bi, C3c or C3d had no effect. The degree of inhibition of dithiobissuccinimidyl propionate (DTSP)-polymerized C3 was proportional to the degree of polymerization, dimer exhibiting less inhibitory activity than larger molecular weight polymers. The inhibitory effect of serum-treated IC and DTSP-polymerized C3b was abrogated by their pretreatment with Fab fragments of anti-C3, or pretreatment of monocytes with Fab fragments of antiserum to the C3b receptor (CR1). We have concluded that the inhibition of C2 production produced by serum-treated IC is due to bound C3b or C3bi, and is mediated by CR1. Furthermore cross linking of receptors is required for this effect; two or more than two receptors must be cross-linked for a significant effect to be observed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6690395      PMCID: PMC1454410     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  27 in total

1.  The hydrolysis of rabbit y-globulin and antibodies with crystalline papain.

Authors:  R R PORTER
Journal:  Biochem J       Date:  1959-09       Impact factor: 3.857

2.  Purification of C3b inactivator and demonstration of its two polypeptide chain structure.

Authors:  D T Fearon
Journal:  J Immunol       Date:  1977-10       Impact factor: 5.422

3.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

4.  Binding of affinity cross-linked oligomers of IgG to cells bearing Fc receptors.

Authors:  D M Segal; E Hurwitz
Journal:  J Immunol       Date:  1977-04       Impact factor: 5.422

5.  Third component of human complement: purification from plasma and physicochemical characterization.

Authors:  B D Tack; J W Prahl
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

6.  Characterization of the human complement (c3b) receptor with a fluid phase C3b dimer.

Authors:  M A Arnaout; J Melamed; B F Tack; H R Colten
Journal:  J Immunol       Date:  1981-10       Impact factor: 5.422

7.  Third component of complement (C3): structural properties in relation to functions.

Authors:  V A Bokisch; M P Dierich; H J Mūller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1975-06       Impact factor: 11.205

8.  The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b).

Authors:  J D Gitlin; F S Rosen; P J Lachmann
Journal:  J Exp Med       Date:  1975-05-01       Impact factor: 14.307

9.  Synthesis of the second component of complement by long-term primary cultures of human monocytes.

Authors:  L P Einstein; E E Schneeberger; H R Colten
Journal:  J Exp Med       Date:  1976-01-01       Impact factor: 14.307

10.  Modulation of the alternative complement pathways by beta 1 H globulin.

Authors:  K Whaley; S Ruddy
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

View more
  3 in total

Review 1.  Complement biosynthesis by mononuclear phagocytes.

Authors:  A R McPhaden; K Whaley
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

2.  Cyclic nucleotides and their relationship to complement-component-C2 synthesis by human monocytes.

Authors:  D Lappin; D W Riches; B Damerau; K Whaley
Journal:  Biochem J       Date:  1984-09-01       Impact factor: 3.857

3.  Isolation and biochemical characterization of the iC3b receptor of Candida albicans.

Authors:  S Alaei; C Larcher; C Ebenbichler; W M Prodinger; J Janatova; M P Dierich
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.